Serine ADP-Ribosylation Depends on HPF1
2017 · Molecular Cell · 350 citations
https://doi.org/10.1016/j.molcel.2017.01.003
Q
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
258
Papers
4.3K
Citations
30
h-index
67
i10-index
Qi Zhang is an academic researcher from The University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Acute Myeloid Leukemia Research & Protein Degradation and Inhibitors & Multiple Myeloma Research and Treatments. The author has an h-index of 30, co-authored 220 publications.
ORCID: 0000-0002-7918-8952Papers by this author
worksComplex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
2023 · Nature Medicine · 348 citations
https://doi.org/10.1038/s41591-022-02103-8
Overview of Research into mTOR Inhibitors
2022 · Molecules · 144 citations
https://doi.org/10.3390/molecules27165295
A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies
2019 · Leukemia · 78 citations
https://doi.org/10.1038/s41375-019-0652-0
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
2023 · Journal of Experimental & Clinical Cancer Research · 25 citations
https://doi.org/10.1186/s13046-023-02750-w
Low-level light treatment ameliorates immune thrombocytopenia
2016 · Scientific Reports · 20 citations
https://doi.org/10.1038/srep38238
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat